{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ADV&page=7",
    "query": {
      "intervention": "ADV",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 363,
    "total_pages": 37,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ADV&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ADV&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T03:04:12.800Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01335347",
      "title": "Safety Study of an Oral Vaccine to Prevent Avian Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Avian Influenza",
        "Bird Flu"
      ],
      "interventions": [
        {
          "name": "ND1.1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo control",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vaxart",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 54,
      "start_date": "2011-04",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2013-01-03",
      "last_synced_at": "2026-10-20T03:04:12.800Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01335347"
    },
    {
      "nct_id": "NCT03266627",
      "title": "Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenovirus",
        "Primary Immune Deficiency Disorder"
      ],
      "interventions": [
        {
          "name": "cytotoxic t-lymphocytes",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "1 Month to 79 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-11-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-08",
      "last_synced_at": "2026-10-20T03:04:12.800Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03266627"
    },
    {
      "nct_id": "NCT05456165",
      "title": "Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colonic Neoplasms",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "GRT-C901",
          "type": "DRUG"
        },
        {
          "name": "GRT-R902",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Adjuvant chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gritstone bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-05-19",
      "completion_date": "2022-09-01",
      "has_results": false,
      "last_update_posted_date": "2024-12-31",
      "last_synced_at": "2026-10-20T03:04:12.800Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05456165"
    },
    {
      "nct_id": "NCT03180216",
      "title": "T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Viral Infections",
        "Bone Marrow Transplant Infection"
      ],
      "interventions": [
        {
          "name": "Virus Specific T cells (VSTs)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's National Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 32,
      "start_date": "2017-02-15",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-10-20T03:04:12.800Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03180216"
    },
    {
      "nct_id": "NCT03490669",
      "title": "Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Pancreatic Cancer",
        "Non Small Cell Lung Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "MSC-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2018-05-21",
      "completion_date": "2019-09-23",
      "has_results": false,
      "last_update_posted_date": "2024-04-05",
      "last_synced_at": "2026-10-20T03:04:12.800Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Grand Rapids, Michigan • Middletown, New Jersey + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03490669"
    },
    {
      "nct_id": "NCT02598388",
      "title": "Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemorrhagic Fever, Ebola"
      ],
      "interventions": [
        {
          "name": "Ad26.ZEBOV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-BN-Filo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 578,
      "start_date": "2015-12-10",
      "completion_date": "2018-12-12",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-10-20T03:04:12.800Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02598388"
    },
    {
      "nct_id": "NCT01035658",
      "title": "Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Doxil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2010-01",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-10-20T03:04:12.800Z",
      "location_count": 4,
      "location_summary": "Fort Myers, Florida • Orlando, Florida • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01035658"
    },
    {
      "nct_id": "NCT07332000",
      "title": "A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Patients Treated by Radiotherapy",
        "Prostate Cancer (Adenocarcinoma)"
      ],
      "interventions": [
        {
          "name": "aglatimagene besadenovec + valacyclovir",
          "type": "BIOLOGICAL"
        },
        {
          "name": "External Beam Radiation Therapy (EBRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2025-10-30",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-20T03:04:12.800Z",
      "location_count": 7,
      "location_summary": "Peoria, Arizona • Lakewood, Colorado • Littleton, Colorado + 4 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07332000"
    },
    {
      "nct_id": "NCT02963831",
      "title": "A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Appendiceal Cancer"
      ],
      "interventions": [
        {
          "name": "ONCOS-102",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2017-09-07",
      "completion_date": "2022-06-25",
      "has_results": true,
      "last_update_posted_date": "2022-12-22",
      "last_synced_at": "2026-10-20T03:04:12.800Z",
      "location_count": 6,
      "location_summary": "San Diego, California • Miami, Florida • Buffalo, New York + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02963831"
    },
    {
      "nct_id": "NCT05009992",
      "title": "Combination Therapy for the Treatment of Diffuse Midline Gliomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Recurrent Diffuse Intrinsic Pontine Glioma",
        "Recurrent Diffuse Midline Glioma, H3 K27M-Mutant",
        "Recurrent WHO Grade III Glioma",
        "WHO Grade III Glioma"
      ],
      "interventions": [
        {
          "name": "ONC201",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Paxalisib",
          "type": "DRUG"
        },
        {
          "name": "DNX-2401",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "2 Years to 39 Years"
      },
      "enrollment_count": 360,
      "start_date": "2021-10-20",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-20T03:04:12.800Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05009992"
    }
  ]
}